Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315409 | 0.89 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2POLBGAAEPHX2 | |
| SCHEMBL14980951 | 0.87 | HPGD (0.49) | ALDH1A1SMN1; SMN2POLBGAAEPHX2 | |
| SCHEMBL3317231 | 0.87 | HDAC3 (0.44) | ALDH1A1 | |
| SCHEMBL17296896 | 0.87 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL3314731 | 0.84 | ALDH1A1 (0.40) | ALDH1A1HPGD | |
| SCHEMBL13417396 | 0.84 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2GAAEPHX2HPGD | |
| SCHEMBL3320774 | 0.84 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2POLBGAAEPHX2 | |
| SCHEMBL3315274 | 0.77 | MAPK1 (0.45) | ALDH1A1GAAEPHX2 | |
| SCHEMBL17296893 | 0.76 | ATM (0.53) | ALDH1A1SMN1; SMN2POLBEPHX2 | |
| SCHEMBL14980948 | 0.76 | NPC1 (0.46) | ALDH1A1POLBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| EP-2129659-B1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | C9, C1R, CBR3 | ALDH1A1 734/4885SMN1; SMN2 4802/4885POLB 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.